IAVI (International AIDS Vaccine Initiative)

New Capabilities

Leading G004 trial; primary driver of germline-targeting vaccine development

In 1984, the U.S. Health Secretary predicted an HIV vaccine within two years. After four decades and dozens of failed trials, IAVI is dosing participants in South Africa with a vaccine that trains the immune system from the ground up rather than simply presenting viral proteins.

Updated May 22